文献速递神经核医学

抗体基活体PET成像检测BACE-1抑制后阿尔茨海默转基因小鼠脑内β-淀粉样蛋白减少

Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition.
PubMed 文献 · J Nucl Med · 2018-05-31

研究在tg-ArcSwe转基因小鼠中评估Aβ原纤维选择性放射性配体124I-RmAb158-scFv8D3的PET成像,发现其脑内信号随年龄增长而升高并与离体放射自显影及Aβ免疫组化结果相符;10月龄小鼠经BACE-1抑制剂NB-360治疗3个月后PET信号显著低于未治疗组并与基线组相近,与死后脑组织Aβ水平下降相符。

要点

  • 124I-RmAb158-scFv8D3的PET信号随tg-ArcSwe小鼠年龄增长而升高,与离体放射自显影和Aβ免疫组化结果相符。
  • 10月龄tg-ArcSwe小鼠经NB-360治疗3个月后活体PET信号显著低于未治疗组,与基线组相近。
  • NB-360治疗小鼠PET所测124I-RmAb158-scFv8D3浓度降低与死后脑组织Aβ水平下降相符。

核心结论

  • Aβ原纤维选择性放射性配体124I-RmAb158-scFv8D3可在tg-ArcSwe小鼠中通过PET成像追踪疾病进展并检测治疗效果。
  • 针对AD的多种治疗处于2期和3期临床试验,但活体研究治疗对重要的非纤维型Aβ形式影响的可能性有限。

研究设计与样本

  • 研究采用tg-ArcSwe转基因小鼠(Aβ病理模型),分为三组:一组7至16月龄小鼠连续接受124I-RmAb158-scFv8D3 PET以随访脑内Aβ病理进展。
  • 第二组10月龄tg-ArcSwe小鼠接受BACE-1抑制剂NB-360治疗3个月,并与未治疗对照组比较。
  • 第三组同为10月龄的tg-ArcSwe小鼠作为基线组接受PET;PET后取脑组织,用ELISA和免疫组化测定Aβ水平。

主要发现

  • 活体PET测得的124I-RmAb158-scFv8D3浓度随年龄增长而升高,并与离体放射自显影及Aβ免疫组化结果相符。
  • 接受NB-360治疗的小鼠活体PET信号显著低于未治疗动物,且与基线动物相近。
  • NB-360治疗小鼠PET定量的124I-RmAb158-scFv8D3浓度降低,与死后脑组织测得的Aβ水平下降相符。

关键数值与推荐

  • 放射性配体为Aβ原纤维选择性124I-RmAb158-scFv8D3,其中RmAb为重组小鼠单克隆抗体,scFv为单链可变片段。
  • BACE-1抑制剂为NB-360,10月龄tg-ArcSwe小鼠治疗3个月。
  • 第一组小鼠年龄范围为7至16月龄。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Visualization of amyloid-β (Aβ) pathology with PET has become an important tool for making a specific clinical diagnosis of Alzheimer disease (AD). However, the available amyloid PET radioligands, such as 11C-Pittsburgh compound B, reflect levels of insoluble Aβ plaques but do not capture soluble and protofibrillar Aβ forms. Furthermore, the plaque load appears to be fairly static during clinical stages of AD and may not be affected by Aβ-reducing treatments. The aim of the present study was to investigate whether a novel PET radioligand based on an antibody directed toward soluble aggregates of Aβ can be used to detect changes in Aβ levels during disease progression and after treatment with a β-secretase (BACE-1) inhibitor. Methods: One set of transgenic mice (tg-ArcSwe, a model of Aβ pathology) aged between 7 and 16 mo underwent PET with the Aβ protofibril-selective radioligand 124I-RmAb158-scFv8D3 (where RmAb is recombinant mouse monoclonal antibody and scFv is single-chain variable fragment) to follow progression of Aβ pathology in the brain. A second set of tg-ArcSwe mice, aged 10 mo, were treated with the BACE-1 inhibitor NB-360 for 3 mo and compared with an untreated control group. A third set of tg-ArcSwe mice, also aged 10 mo, underwent PET as a baseline group. Brain tissue was isolated after PET to determine levels of Aβ by ELISA and immunohistochemistry. Results: The concentration of 124I-RmAb158-scFv8D3, as measured in vivo with PET, increased with age and corresponded well with the ex vivo autoradiography and Aβ immunohistochemistry results. Mice treated with NB-360 showed significantly lower in vivo PET signals than untreated animals and were similar to the baseline animals. The decreased 124I-RmAb158-scFv8D3 concentrations in NB-360-treated mice, as quantified with PET, corresponded well with the decreased Aβ levels measured in postmortem brain. Conclusion: Several treatments for AD are in phase 2 and 3 clinical trials, but the possibility of studying treatment effects in vivo on the important, nonfibrillar, forms of Aβ is limited. This study demonstrated the ability of the Aβ protofibril-selective radioligand 124I-RmAb158-scFv8D3 to follow disease progression and detect treatment effects with PET imaging in tg-ArcSwe mice.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Meier SR, Syvänen S, Hultqvist G, et al. Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition. J Nucl Med. 2018. PMID: 29853653. doi:10.2967/jnumed.118.213140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。